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Abstract
Aims: Bone is the most frequent site of prostate cancer (PCa) metastasis. Tumor cells interact with the bone
microenvironment interrupting tissue balance. Heme oxygenase-1 (HO-1; encoded by Hmox1) appears as a
potential target in PCa maintaining the cellular homeostasis. Our hypothesis is that HO-1 is implicated in
bone physiology and modulates the communication with PCa cells. Here we aimed at (i) assessing the
physiological impact of Hmox1 gene knockout (KO) on bone metabolism in vivo and (ii) determining the
alterations of the transcriptional landscape associated with tumorigenesis and bone remodeling in cells growing
in coculture (PCa cells with primary mouse osteoblasts [PMOs] from BALB/c Hmox1+/+, Hmox1+/-, and
Hmox1-/- mice).
Results: Histomorphometric analysis of Hmox1-/- mice bones exhibited significantly decreased bone density
with reduced remodeling parameters. A positive correlation between Hmox1 expression and Runx2, Col1a1,
Csf1, and Opg genes was observed in PMOs. Flow cytometry studies revealed two populations of PMOs with
different reactive oxygen species (ROS) levels. The high ROS population was increased in PMOs Hmox1+/-
compared with Hmox1+/+, but was significantly reduced in PMOs Hmox1-/-, suggesting restrained ROS tolerance
in KO cells. Gene expression was altered in PMOs upon coculture with PCa cells, showing a pro-osteoclastic
profile. Moreover, HO-1 induction in PCa cells growing in coculture with PMOs resulted in a significant modu-
lation of key bone markers such as PTHrP and OPG.
Innovation and Conclusion: We here demonstrate the direct implications of HO-1 expression in bone re-
modeling and how it participates in the alterations in the communication between bone and prostate tumor cells.
Antioxid. Redox Signal. 32, 1243–1258.
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Prostate cancer (PCa) is the second-most frequentlydiagnosed cancer and the fifth leading cause of cancer-
related deaths in men worldwide (5a). PCa progression is
dominated by a constant tumor adaptation (32, 40). The
acquisition of resistance to androgen deprivation therapy
coincides with PCa bone metastases in most cases, indicating
the presence of a bone/epithelial interaction that drives
organ-specific progression. Bidirectional interaction between
bone cells and PCa cells suggests that not only growth factors
derived from the tumor can affect bone cells but also that
cells from the bone microenvironment stimulate metastatic
tumor growth (32, 37, 62).
Bone is a mineralized connective tissue that has four main
cell types: osteoblasts, bone ‘‘lining’’ cells, osteocytes, and
osteoclasts (14). This tissue has important functions such as
locomotion, support and protection of soft tissues, calcium
and phosphate reservoir, and bone marrow shelter (12, 52).
Bone is a highly dynamic organ that is continuously degraded
by osteoclasts and regenerated by osteoblasts (5, 9, 33, 56).
Osteoblasts are responsible for bone formation, synthesizing
and secreting proteins to form the osteoid, which will then be
mineralized and converted to mature bone (11). These cells
derive from mesenchymal stem cells (MSCs), which can also
be differentiated to other cell types, including adipocytes and
chondrocytes (51). The commitment of MSCs toward a lineage
of bone progenitor cells requires the expression of specific
genes, followed by temporarily programmed steps that include
the synthesis of bone morphogenetic proteins (BMPs) and
members of the Wnt pathway (18). The expression of Runt-
related transcription factor 2 (Runx2), Dlx5, and Osx is crucial
for osteoblast differentiation (7, 64).
Osteoclasts are differentiated multinucleated cells that
originate from mononuclear cells of hematopoietic stem cell
lineage, under the influence of several factors (25). These
factors include the macrophage colony stimulating factor
(M-CSF or CSF-1), secreted by bone progenitor mesenchy-
mal cells and osteoblasts, and RANKL (receptor activator for
nuclear factor j B ligand), secreted by osteoblasts, osteo-
cytes, and stromal cells (42). The RANKL/RANK (receptor
activator for nuclear factor j B)/OPG (osteoprotegerin) axis
is the main mediator of osteoclastogenesis (49).
The bone remodeling process is a highly complex cycle
that is carried out by the concerted action of the cell types
described above (52). Systemic factors for bone homeostasis
maintenance include parathyroid hormone (PTH), calcitonin,
1,25-dihydroxy vitamin D3 (calcitriol), glucocorticoids, an-
drogens, and estrogens (6, 36, 59, 70). PTH-related protein
(PTHrP), which also binds to the PTH receptor, has been
reported to influence bone remodeling (6).
PCa cell bone affinity may owe to the expression of genes
that predispose cells to lodge in the bone marrow, although it
is also possible that these cells acquire osteomimetic prop-
erties after being located within the bone compartment. Once
in the bone, disseminated tumor cells or their progeny may
have osteoblastic, osteoclastic, or both effects (13, 54). Me-
tastatic tumor cells are not the only ones responsible for
inducing bone destruction/formation. This process mainly
involves osteoblasts and osteoclasts. PTHrP, interleukin
(IL)-1, IL-6, and prostaglandin E2 (PGE2) can regulate the
osteoblast production of RANKL/OPG and modulate osteo-
clast activation (44).
The concept that there are basically two types of bone
metastases—osteoblastic or osteoclastic—might be too sim-
plistic. The processes of resorption and bone formation are
usually linked or coupled. There is plenty of evidence that both
processes are activated in the majority of bone metastases (44).
Reactive oxygen species (ROS) can cause severe tissue
damage due to the accumulation of changes in vital mac-
romolecules. Currently, the mechanisms by which cells
sense pro-oxidant states and activate signaling pathways to
counteract changes are not completely known. However, the
expression of heme oxygenase (HO) family enzymes (heme
catabolizers) is a well-preserved strategy throughout evo-
lution to counteract ROS (39).
HO-1 is a 32 kDa protein inducible through a variety of
stimuli, including ROS and inflammatory cytokines (46). It is
well known that inflammation favors PCa and its progression
(41). Proinflammatory factors secreted by PCa and bone cells
and the subsequent release of bone matrix factors mediate the
paracrine/autocrine interaction between PCa cells, osteo-
blasts, and osteoclasts, ultimately determining the bone
phenotype and PCa progression (15, 22). Oxidative stress is
a natural consequence of the inflammatory process and acts
as a modulator for the mineralized tissue function (63).
We previously demonstrated that HO-1 participates in PCa
bone metastasis, restoring osteoblast proliferation (16), which
was shown to be significantly inhibited by coculturing PC3
cells with primary mouse osteoblasts (PMOs) (67). We also
found that HO-1 is capable of modulating signaling pathways
relevant to bone metastasis, such as FoxO/b-catenin, and
promotes bone remodeling when tumor cells are transplanted
into the femur of SCID mice (16). More recently, we reported
that HO-1 modulates cellular adhesions in PCa, increasing
E-cadherin and b-catenin levels and its subsequent relocation
to the plasma membrane, favoring a more epithelial pheno-
type (21).
We also reported that HO-1 induction alters the expression
of different cytoskeletal genes and is associated with key
factors that induce the remodeling of actin filaments in the
filopodia, increasing adhesion and decreasing PCa cell in-
vasiveness (48). However, the effect of HO-1 deficiency in
the bone physiology and in the communication between PCa
cells and cells of the bone stroma is yet to be fully explored.
Here, we thoroughly describe the direct effect of heme
oxygenase-1 gene (Hmox1) total, partial, or absent expres-
sion in impairing bone turnover and remodeling. We further
Innovation
Advanced prostate cancer exhibits bone dissemination
as the preferable site for metastasis accompanied by an
average survival of *40 months. Bone metastases are
incurable and only palliative treatments are available. Our
results showcase for the first time the direct effect of the
heme oxygenase-1 gene (Hmox1 gene) on bone turnover
and remodeling and demonstrate that its modulation on
both prostate tumor cells and bone cells changes their
communication altering the tumoral bone niche. A better
understanding of how these processes influence the early
onset of bone metastasis can shed light into more tailored
therapies.
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established coculture system models of human PCa cells with
PMOs from Hmox1 transgenic mice, and delineated a set
of osteoblastic and osteolytic genes (PTHrP, OPG, and
RANKL) and analyzed how HO-1 expression levels affected
this signature.
Results
Morphological, genetic, and physiological
characterization of bone from knockout Hmox1 mice
We have previously used a coculture system of PC3 cells
with PMOs to show that the decrease in PMO proliferation
induced by tumor cells was restored when these cells were
treated with hemin, a specific pharmacological inducer of
HO-1. Hemin treatment increased the expression of DKK1
(inhibitor of Wnt/b-catenin pathway in bone remodeling) in
cocultured PC3 cells, redirecting b-catenin toward the FoxO
pathway in osteoblasts and activating the transcription of
factors involved in counteracting oxidative stress. In addi-
tion, the intrabone inoculation of PCa cells overexpressing
HO-1 (PC3HO-1) produced a robust bone remodeling (16).
These findings suggested that HO-1 plays a key role in the
control of inflammation, oxidative stress, and angiogenesis,
which in turn altered the tumor microenvironment impacting
on PCa bone progression.
In this work, we evaluated by histomorphometric analysis
of femurs from male BALB/c Hmox1+/+ (wild-type [WT]);
Hmox1+/- (heterozygous [Het]); Hmox1-/- (knockout [KO])
mice, the involvement of HO-1 on bone remodeling. We also
investigated the role of HO-1 deficiency in the communica-
tion through released soluble factors between osteoblasts and
prostatic cancer cells, using a coculture system of PMOs
isolated from the calvaria of the Hmox1 transgenic animals
and PC3 cells.
Histomorphometric analysis of femurs of the different
groups was carried out to characterize the animal model and
evaluate whether the different genetic backgrounds resulted
in alterations in the physiology and, therefore, in the mor-
phology of the bone tissue. Our results showed a significant
decrease in bone volume, bone density, and trabecular bone
density, with an increase in the average distance between
trabeculae, in the Hmox1-/- versus Hmox1+/+ animals (Figs. 1
and 2A). In agreement with these results, a reduction was also
seen in all the static parameters of bone formation, with a
total loss of the osteoid surface (OS; used as a bone neo-
formation parameter), consistent with a reduction in the
number of osteoblasts (Figs. 1A and 2B). Accordingly, a
decrease in osteoclast number was observed, and the conse-
quent reduction of the static resorption parameters (Figs. 1B
and 2C).
Considering the differences observed at the morphological
level, we next sought to evaluate if these alterations could be
explained by changes in the expression of genes related to
bone metabolism. For this purpose, PMOs were isolated from
the calvaria of the Hmox1+/+, Hmox1+/-, and Hmox1-/- ani-
mals, and the expression of genes involved in bone physi-
ology was analyzed by real-time quantitative polymerase
chain reaction (RT-qPCR). We found a direct correlation
between expression levels of Hmox1 and genes such as
Runx2—osteoblast early differentiation associated gene—
Col1a1—involved in the deposition of the collagen matrix—
and Csf-1, Opg—secretion proteins that modulate osteoclast
differentiation/activation (Fig. 3A). Other critical molecules
involved in the activation and function of osteoclasts, such as
Opn—mediates osteoclast adhesion for bone resorption—Il-
6—osteoclast differentiation/activation modulator—and
Rankl—osteoclast differentiation factor, showed a behavioral
pattern independent of Hmox1 levels (Fig. 3A).
It was previously reported that HO-1 confers cytoprotec-
tion against inflammation and oxidative stress in several
animal models (20). Oxidative stress is a natural consequence
of the inflammatory process and acts as a modulator of the
function of mineralized tissues (63). This impacts bone for-
mation by inhibiting osteoblast differentiation and by pro-
moting apoptosis (2). These effects are mediated, in part, by
ROS generated in the context of oxidative stress. Taking this
into account, we next evaluated ROS levels in PMOs ob-
tained from Hmox1+/+, Hmox1+/-, and Hmox1-/- mice by
flow cytometry (Fig. 3B). A lower percentage of DCF+ cells
in the Hmox1-/- PMOs were observed when compared with
those from the Hmox1+/+ or Hmox1+/- animals (Fig. 3B.I).
When analyzing the frequency distribution for the DCF
FIG. 1. Histological section of femurs of BALB/c
Hmox11/1, Hmox1+/-, and Hmox1-/- mice. (A) Staining
with toluidine blue for the analysis of osteoblasts (black
arrows) and osteoid (red arrows); or (B) staining for TRAP.
Red arrows indicate mature osteoclasts, yellow arrows in-
dicate monocytes, and black arrows show eroded areas. The
images at the left column are montages of images taken with
20 · objective. Hmox1, heme oxygenase-1 gene; TRAP, acid
phosphatase tartrate resistant. Color images are available
online.
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FIG. 2. Histomorphometry analysis of femurs of BALB/c Hmox1+/+ (WT), Hmox+/- (Het); Hmox1-/- (KO) mice.
Dot-plot graphs depicting (A) different bone structural parameters, (B) static formation parameters and (C) static resorption
parameters. In each case, the statistical significance ( p value) is expressed with respect to the values obtained for the WT
animals. p Value in red indicates significant differences. BS/TV, bone surface/tissue volume; BV/TV, bone volume/tissue
volume; ES/BS, eroded surface/bone surface; N.Ob/B.Pm, osteoblasts/bone perimeter; N.Ob/O.Pm, osteoblasts/osteoid
perimeter; N.Ob/T.A, osteoblasts/total area; N.Oc/B.Pm, osteoclasts/bone perimeter; N.Oc/B.Pm, osteoclasts/bone perim-
eter; N.Oc/T.A, osteoclasts/total area; Ob.S/BS, osteoblast surface/bone surface; OS/BS, osteoid surface/bone surface;
Os(Ob+)/BS, osteoid surface lined with osteoblast/bone surface; Tb.N, trabecular number; Tb.Sp, trabecular separation;
Tb.Th, trabecular thickness; WT, wild type. Color images are available online.
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signal intensity (Fig. 3B.II), we identified two cell popula-
tions: ‘‘High’’ and ‘‘Low.’’ In addition, the ‘‘Low’’ popula-
tion of Hmox1+/- and Hmox1-/- cells had a slightly lower
fluorescence intensity compared with Hmox1+/+ PMOs. On
the contrary, the ‘‘High’’ populations had the same intensity,
but the frequency was higher in Hmox1+/- PMOs when
compared with the Hmox1+/+ PMOs. The frequency of cells
in the ‘‘High’’ population for the Hmox1-/- PMOs was barely
present (Fig. 3B.III). Overall, these results might suggest that
in the PMOs from the Hmox1 heterozygous animals, the in-
crease in the ‘‘High’’ population might be due to the fact that
these cells had fewer copies of Hmox1 (compared with WT
animals), and therefore, a decreased ability to maintain redox
homeostasis. In addition, in the case of Hmox1-/- PMOs, a
striking decrease in the ‘‘High’’ population was observed,
indicating that HO-1 loss might establish a maximum limit in
ROS level tolerance for these cells. However, we cannot
discard the possibility that the imbalance in the antioxidant
state, produced as a consequence of Hmox1 loss, could trigger
the activation of other antioxidant pathways.
Role of Hmox1 expression in osteoblasts
upon interaction with PCa cells
Given the morphological, physiological, and genetic dif-
ferences observed in the bones of animals with the different
Hmox1 genetic backgrounds, we next analyzed the effect of
the coculture of PC3 cells (pretreated or not with hemin,
specific HO-1 chemical inducer) with PMOs isolated from
Hmox1+/+, Hmox1+/-, and Hmox1-/- animals to understand
the relevance of HO-1 in bone metastases.
First, we compared ROS levels in PMOs from the three
groups of animals between the different coculture conditions
(Fig. 4A). Only the Hmox1+/- PMOs showed an increase in
the percentage of DCF+ cells when cocultured with PCa
cells, whether they were pretreated or not with hemin
(Fig. 4B). Considering the results from Figures 3B and 4, the
stressor effect generated by the presence of PCa cells was
evident only in Hmox1+/- PMOs due to the diminished reg-
ulatory capacity. It is possible given that Hmox1 levels are
lower in Hmox1+/- compared with WT animals, this decrease
in Hmox1 expression may have more significant conse-
quences, evidenced by increased ROS levels in these cells.
Taking into consideration that a decrease in Hmox1 levels
is also seen in WT animals, this reduction in Hmox1 net levels
may not be as lower as in Hmox1+/- animals, and hence may
be sufficient enough to counteract oxidative stress. The next
step was to evaluate Hmox1 gene expression in the coculture
system. Messenger RNA (mRNA) levels of Hmox1 in both the
Hmox1+/+ and Hmox1+/- PMOs were negatively modulated
upon coculture with PC3 cells (pretreated or not with hemin)
(Fig. 4C.II, III). Given that Hmox1 expression levels in PMO
KO were extremely low (Fig. 4C.I), RT-qPCR quantification
for this gene in PMO KO cocultured with PC3 cells was not
sensitive enough for an accurate Hmox1 determination.
When analyzing the coculture effect on the expression of
bone remodeling genes (Fig. 5A) in the Hmox1+/+ PMOs, we
found that the presence of tumor cells had a negative impact
on Opg and Csf-1 expression, and this effect was maintained
when PCa cells were pretreated with hemin (Fig. 5B–D).
Furthermore, Rankl expression was positively regulated by
the coculture (Fig. 5). This increase in addition to the
FIG. 2. (continued).
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decrease in Opg would cause an imbalance in the Rankl/Opg
ratio that might favor the osteoclast activation in the bone
microenvironment (Fig. 5A). Although hemin pretreatment
of tumor cells had no further effect on Opg expression in
Hmox1+/+ PMOs after coculture, it was able to prevent the
increase in Rankl expression. In line with this, the coculture
with PCa cells pretreated with hemin induced an increase in
the expression of Runx2 in Hmox1+/+ PMOs (Fig. 5B),
leading toward a less pro-osteoclastic profile. Other genes such
as Il-6 suffered a small decrease, which was only significant
compared with the coculture with PC3 cells pretreated with
hemin (Fig. 5B). Col1a1 and Opn were not affected in any of
the assayed conditions (Fig. 5B).
Regarding Opg, Runx2, Csf-1, and Opn expression in
Hmox1+/- PMOs (Fig. 5C), we observed the same effect
described for Hmox1+/+ PMOs. These results suggest that the
response is not affected by Hmox1 basal levels in bone cells.
Moreover, even in Hmox1-/- PMOs, the coculture effects on
FIG. 3. Expression of bone remodeling genes and oxidative stress levels in primary mouse osteoblasts isolated from
Hmox1+/+, Hmox1+/-; Hmox1-/- mice calvariae. (A) Correlation in the expression of genes involved in bone remodeling
with respect to Hmox1. Gene expression levels (relative to 36b4) measured by RT-qPCR: (I) Runx2; (II) Col1a1; (III) Csf-
1; (IV) Opg; (V) Il-6; (VI) Opn and (VII) Rankl, expressed as a function of the levels of Hmox1 in PMOs isolated from
BALB/c Hmox1+/+, Hmox1+/-, and Hmox1-/- mice. Color of the dots represents the specific genotype of the Hmox1+/+
(green dots), Hmox1+/- (yellow dots), and Hmox1-/- (red dots). The data were subjected to a linear regression. In each case, the
statistical significance ( p value) is expressed for the linear regression obtained. p Value in red indicates significant differences.
(B) ROS levels in PMOs measured by flow cytometry in the FITC channel, using DCFDA as a probe. (I) shows the percentage
of FITC+ cells for PMOs Hmox1+/+, Hmox1+/-, Hmox1-/-; (II) shows a representative histogram for FITC intensity for PMOs
Hmox1+/+ (green), Hmox1+/- (yellow), Hmox1-/- (red), and autofluorescence (blue); (III) shows the percentage distribution of
FITC+ cells in each intensity population (High or Low). Results are expressed as mean – SD. Hmox1+/+: *p < 0.05; **p < 0.01.
Statistical difference with respect to the PMOs Hmox1+/-; ++p < 0.05. Col1a1, collagen type I alpha 1 chain; CSF-1, colony
stimulating factor 1; DCFDA, 5-(and-6)-carboxy-2¢,7¢-dichlorofluorescein diacetate; FITC, fluorescein isothiocyanate; PMOs,
primary mouse osteoblasts; ROS, reactive oxygen species; RT-qPCR, real-time quantitative polymerase chain reaction; SD,
standard deviation. Color images are available online.
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Opg, Runx2, and Opn expression are preserved, whereas the
expression of Csf-1 is only affected by the presence of tumor
cells pretreated with hemin (Fig. 5D). The loss of Hmox1
avoided the effect of the coculture on Il-6 expression, evi-
denced by the lack of changes in Hmox1+/- and Hmox1-/-
PMOs, under the tested conditions (Fig. 5C, D). Conversely,
an increase in Col1a1 expression was evident in Hmox1+/-
PMOs when cocultured in the presence of hemin pretreated
PC3 cells (Fig. 5C). This change in Col1a1 expression could be
evidenced in Hmox1+/- PMOs due to the lower basal levels of
FIG. 4. Co-culture of primary mouse osteoblasts isolated from Hmox1+/+, Hmox1+/-, Hmox1-/- mice calvaria and
PC3 cells. (A) Coculture system representation. (B) Upper panel (I) depicts levels of ROS measured in PMOs (Hmox1+/+,
Hmox1+/-, Hmox1-/-) under the different coculture conditions by flow cytometry, in the FITC channel using a DCFDA probe. Lower
left panel (II) shows FITC+ cells in Hmox1+/- PMOs cultured under the experimental conditions detailed in the figure. Lower right
panel (III) shows representative histograms for the intensity of FITC in PMOs Hmox1+/- in the coculture experimental conditions.
*p < 0.05. (C) Upper panel (I) shows the expression levels of Hmox1 assessed by RT-qPCR in PMOs. Lower panels show the
coculture effect with PC3 cells or PC3 cells pretreated with hemin (50lM; 24 h), on the expression of Hmox1 in PMOs (II) Hmox1+/+
or (III) Hmox1+/-. The values were relativized using 36B4 as a reference gene and normalized with respect to the control condition.
Results are expressed as mean – SD. *p < 0.05; **p < 0.01; ***p < 0.001. Color images are available online.
‰
FIG. 5. Expression of bone remodeling genes under co-culture of primary mouse osteoblasts isolated from Hmox1+/+,
Hmox1+/-, Hmox1-/- mice calvaria and PC3 cells. (A) Schematic representation of soluble factors implicated in the com-
munication between PCa and bone cells. Expression levels of (I) Opg, (II) Rankl, (III) Runx2, (IV) Col1a1, (V) Csf-1, (VI) Il-6,
and (VII) Opn assessed by RT-qPCR in (B) Hmox1+/+ PMOs, (C) Hmox1+/- PMOs, or (D) Hmox1-/- PMOs grown alone or in
coculture with PC3 cells or PC3 cells pretreated with hemin (50lM; 24 h). The values were relativized using 36B4 as a
reference gene and normalized with respect to the control condition. Results are expressed as mean – SD. *p < 0.05; **p < 0.01;
***p < 0.001. PCa, prostate cancer. Color images are available online.
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this gene with respect to Hmox1+/+ PMOs. In the case of
Hmox1-/- PMOs, both experimental conditions led to a de-
crease in the expression of Col1a1 (Fig. 5D), showing a change
in the coculture effect due to the lack of HO-1 in PMOs.
Although the increase in Rankl expression due to the co-
culture effect with PCa cells is still observed in Hmox1+/-
PMOs (Fig. 5C), the coculture with hemin pretreated tumor
cells was not able to prevent Rankl induction, as observed in
Hmox1+/+ PMOs. On the contrary, the coculture with PCa
cells was not able to induce the expression of Rankl in os-
teoblasts lacking Hmox1, while the presence of hemin pre-
treated tumor cells caused a significant overexpression of
Rankl in Hmox1-/- PMOs (Fig. 5D). These results imply that
the coculture effect on Rankl expression is modulated by
HO-1 not only in the tumor cell but also in the osteoblast.
In the same way, the effect of the coculture was assessed in
PCa cells. First, HMOX1 levels were measured, resulting in
no significant alteration when the tumor cells were cocultured
with the PMOs (Fig. 6A). When tumor cells were pretreated
with hemin, the induction of HMOX1 was maintained in
comparison with the coculture with Hmox1+/+ PMOs, while
the coculture with both Hmox1+/- and Hmox1-/- PMOs par-
tially reversed the effect of the hemin pretreatment on
HMOX1 levels in the PCa cells (Fig. 6A).
As previously mentioned, PTHrP can be produced by tu-
mor cells with implications not only for the tumor cell but for
bone physiology as well (44). Under our experimental con-
ditions, PTHrP expression was increased in PC3 cells co-
cultured with PMOs, independent of the genotype (Fig. 6B).
Hemin pretreatment was able to prevent the induction of
PTHrP in the coculture with Hmox1+/+ PMOs. This preven-
tive capacity of hemin pretreatment was not only lost when
tumor cells were cocultured with Hmox1+/- PMOs but also
enhanced the coculture effect when tumor cells were grown
in the presence of Hmox1-/- PMOs (Fig. 6B).
The PC3 cells express OPG (27). As observed for PTHrP,
OPG expression increased in tumor cells that had been co-
cultured with Hmox1+/+ or Hmox1+/- PMOs, and this effect
was prevented by hemin pretreatment (Fig. 6C). Besides, the
coculture with Hmox1-/- PMOs negatively affected the ex-
pression of OPG in the tumor cells, independently of whether
they had been pretreated with hemin (Fig. 6C).
In the case of DKK1, a critical factor in bone remodeling,
acting as an inhibitor of the Wnt/b-catenin pathway (45), its
expression was upregulated in tumor cells cocultured with
Hmox1+/+ or Hmox1+/- PMOs, but not when cocultured with
Hmox1-/- PMOs (Fig. 6D).
In summary, hemin pretreatment modulated the response
of tumor cells to the coculture with the PMOs, and this
modulation was different depending on the PMO Hmox1
genetic background. This clearly suggests that the HO-1 level
in the PMOs is not only important for their physiology but is
also relevant for their interaction with the tumor cells.
Discussion
Bone is a dynamic tissue that undergoes homeostatic re-
modeling mediated by the balanced activities of osteoblasts
and osteoclasts (34). HO-1 plays a critical role in the physi-
ology of this process (34, 55, 61). HO-1 was shown to maintain
bone mass during physiological bone remodeling (34).
The histomorphometric analysis of mice femurs for the
different genetic backgrounds (Hmox1+/+, Hmox1+/-, and
Hmox1-/-) presented in this work showed a decrease in bone
volume concomitant with the loss of Hmox1. In line, a lower
number of osteoblasts were observed, with the consequent
reduction of osteogenic parameters. These results are con-
sistent with the functions previously described for HO-1 (4,
60, 61). It was reported that HO-1 expression and activity are
essential for the differentiation of MSCs toward an osteo-
blastic lineage, as well as vital for their growth (61). In ad-
dition, the inhibition of HO-1 favors the differentiation of
MSCs toward the formation of adipocytes, with a decrease in
osteoblast formation (4, 60, 61).
Although HO-1 induction was demonstrated to impair
osteoclast differentiation (17, 34, 71) in transgenic mice, we
showed that Hmox1 deficiency downregulated osteoclast
number and activity. These results may appear contradictory
at first. However, and taking into account the physiological
context, the osteoblastic lineage is the main modulator of
osteoclast differentiation and activation, so that the observed
FIG. 6. Gene expression analyses in PC3 cells growing
in co-cutlure with primary mouse osteoblasts isolated
from Hmox1+/+, Hmox1+/-, Hmox1-/- mice calvaria. Ex-
pression levels of (A) HMOX1, (B) PTHrP, (C) OPG, and (D)
DKK1, assessed by RT-qPCR in PC3 cells pretreated or not with
hemin (50lM; 24 h), grown alone or in coculture (24 h) with
PMOs Hmox1+/+; Hmox1+/-; and Hmox1-/-. The values were
relativized using PPIA as a reference gene and normalized with
respect to the control condition. Results are expressed as
mean – SD. Statistical significance with respect to control:
**p < 0.01; ***p < 0.001; or hemin: $p < 0.05; $$p < 0.01;
$$$p < 0.001. DKK1, inhibitor of Wnt/b-catenin pathway in bone
remodeling. Color images are available online.
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decrease in osteoblast number and activity in Hmox1-defi-
cient mice may explain the decrease observed in both bone
metabolism and osteoclast differentiation and activation.
These results are further supported by the altered expression
found in genes involved in osteoblast differentiation and/or
regulation of bone physiology, concurrent with the general
decrease in bone metabolism.
It was reported that the reduction in ROS levels mediated
by HO-1 canonical activity, allowed the restoration of os-
teoblastic markers (4, 61). The PMOs isolated from the
calvaria of mice used in this study showed heterogeneous
levels of ROS within each genotype, identifying two popu-
lations with Low- and High-ROS levels. In the case of
Hmox1-/- PMOs, a striking decrease in the ‘‘High’’ popu-
lation was observed, indicating that HO-1 loss might es-
tablish a maximum limit in ROS level tolerance for these
cells, acting as a positive selection factor on cells with low
levels of ROS and therefore with a decreased oxidative
metabolism.
Of note, when working with PMOs, it is worth mentioning
that the isolation of this particular cell linage requires HO-1
for differentiation (4, 60, 61); hence, Hmox1 deficiency might
also severely impact on the number of PMOs. This evidence
is in line with the histomorphometry analysis performed in
this work, depicting a decrease in bone metabolism when
analyzing the osteoblasts from femurs of KO Hmox1 trans-
genic mice compared with WT and/or heterozygous femurs.
Whether the High-ROS level cell population, during the an-
imal development, did initially exist in abundance and was
then lost—unable to survive in a high ROS condition— is
still to be elucidated.
Regarding the metastatic process, resorption may be a
necessary step for tumor cell homing to bone (69). The
consequent bone destruction releases growth factors such as
transforming growth factors b (TGF-bs) and BMPs from the
mineralized bone matrix, further enhancing tumor growth
and survival in a vicious cycle (22). Tumor cells can stimu-
late osteoclast activity by directly altering the RANKL/OPG
ratio, or secreting signaling molecules such as PTHrP to
stimulate RANKL production by osteoblast (35, 66).
Considering the involvement of HO-1 in osteoblast dif-
ferentiation (60), we next studied the effect of cocultures of
human PCa cells (pretreated or not with hemin) and the WT
or Hmox1-deficient PMOs. PCa cell coculture altered PMO
gene expression, leading toward a pro-osteoclastogenic pro-
file over an osteoblastic function. Hemin pretreated tumor
cells could be modulating the interaction by soluble factors of
cancer cells with PMOs, leading toward a more pro-
osteoblastic profile. The observed changes on PMOs may be
partly explained by the expression changes in PTHrP in the
tumor cells. PTHrP was first isolated from human carcinomas
(26, 29) and it is one of the main agents for the humoral
hypercalcemia associated with various malignancies (19).
PTHrP is structurally associated with PTH, a hormone of
vital importance in calcium metabolism (53). PTHrP is a key
factor in osteolytic bone metastasis, it increases the produc-
tion of RANKL and decreases the secretion of OPG from the
osteoblasts and stromal cells (30), favoring osteoclastogen-
esis; however, its direct effects on osteoclasts remain elusive.
In addition, breast and PCa cells that produce osteolytic
metastases (i.e., MDA-MB-231, MDA-MB-435s, PC3) se-
creted PTHrP (23, 68). These results suggest that PTHrP
could play a pivotal role in bone metastases formation and/or
development. Conversely, engineered overexpression of
PTHrP in breast or PCa cells increased metastases to the bone
compartments and osteoclast-mediated bone destruction at
the tumor/bone interface (24, 65).
Of note, PTHrP overexpression did not affect the forma-
tion of metastases to nonbone sites (24), and a PTHrP neu-
tralizing antibody had no effect on visceral metastases caused
by SBC-5 cells (43), suggesting an exclusive role of PTHrP
on bone metastases (19). These results highlight the in-
volvement of HO-1 in bone and tumor cell communication
mediated by soluble factors. It is well known that PTHrP
negatively regulates OPG (32). However, our results show-
cased that when PMOs, WT, were cocultured with PC3 cells
pretreated with hemin, no changes were observed in PTHrP
in PC3 cells, but Opg was downregulated in the PMOs. Thus,
Opg modulation is clearly affected by other factors. In this
regard, DKK1 might be involved in Opg downregulation in
PMOs. DKK1 stimulates growth and osteolytic bone me-
tastasis in PCa (50, 57).
Patients with multiple myeloma have DKK1 increased
levels in the bone compartment, and thus, it has been pro-
posed as an osteoblast suppression mechanism (19, 58).
Furthermore, PC3 cells express and release DKK1 and si-
lencing of this molecule resulted in an osteolytic to osteo-
blastic phenotypic shift (10, 50). DKK1 inhibits OPG release
from osteoblasts (50). Thus, the decrease in Opg in WT and
Het PMOs could be partly explained by the increase in DKK1
expression in PC3 cells when cocultured with PMOs. On the
contrary, a drop in Opg expression is also seen in KO PMOs,
but in this case, it appears not related to the DKK1 produced
by the tumor cell, since no changes are seen in DKK1 ex-
pression in PC3 cells when cocultured with KO PMOs. In line
with these results, OPG increases in human bone metastases
compared with both primary tumor and nodule metastasis (8).
PC3 cells express OPG (28), however, they do so at signifi-
cantly lower levels compared with bone marrow stromal cells
(47). This might suggest that beyond OPG bone function, the
observed changes in OPG levels in malignant cells could
have direct implications on the tumor since OPG can act as a
decoy TRAIL receptor decreasing apoptosis mediated by this
factor (27).
Figure 7 summarizes our proposed model on the crosstalk
between tumor cells and PMOs, where the increase in
PTHrP levels in tumor cells by the coculture stimulates
Rankl expression in the PMOs (Hmox1+/+ and Hmox1+/-).
This mechanism would favor the osteoclast differentiation
and activation in the bone microenvironment. Hemin pre-
treatment of PCa cells interferes in the interaction with bone
cells, preventing the stimulation of PTHrP in the tumor cell
and the consequent change in Rankl levels in Hmox1+/+
PMOs, favoring a pro-osteoblastic profile. This modulatory
effect is lost when compared with the Hmox1+/- PMO cocul-
ture, where despite hemin pretreatment, the induction of
PTHrP in the tumor cell is maintained and therefore Rankl
increases in the Hmox1+/- PMOs. Finally, this mechanism re-
sults less sensitive in Hmox1-/- PMOs, since a greater increase
in PTHrP levels in the tumor cell is required for an increase in
Rankl levels in the Hmox1-/- PMOs to be evident (Fig. 7).
The molecular mechanisms that govern the distortion of
the bone remodeling process occurring in metastatic cancer
invading the bone are still poorly understood. The present
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results reveal the importance of HO-1 expression in bone,
not only for the physiology of bone cells but also in the
modulation of the communication between PMOs and PCa




All animal experiments were conducted in accordance
with the Animal Research: Reporting of In Vivo Experi-
ments guidelines. Eight-week-old male BALBc/Hmox1+/+,
Hmox1+/,- or Hmox1-/- mice, initially provided by Dr. Saw
Feng-Yet, were housed in the animal facility of the Ex-
perimental Obstetrics and Gynecology of the Medical Fa-
culty, Otto-von-Guericke University, Magdeburg.
PMO isolation
PMOs were isolated from the calvaria of mice (three per
group per experiment) following the procedure described by
Bakker and Klein-Nulend (3), with slight modifications. In
brief, after dissection, calvarias were cut into small pieces
and digested for 30 min in a shaking incubator at 37C in
4 mL of a-MEM containing 2 mg/mL collagenase P (Roche
Diagnostic GmbH, Mannheim, Germany). After this time,
the last step was repeated by renewing the collagenase so-
lution P. Then, the bone pieces were incubated (30 min in a
shaking incubator at 37C) in a solution of 2.5% trypsin plus
0.1% EDTA (Life Technologies, Inc.) in phosphate-buffered
saline (PBS). A final incubation with collagenase P solution
was performed (30 min in a shaking incubator at 37C). The
bone fragments were rinsed with a-MEM plus penicillin,
streptomycin, and 10% fetal bovine serum (FBS). This last
procedure was repeated three times, each time. Finally, the
bone pieces were plated in three 25 cm2 flasks containing
a-MEM plus penicillin, streptomycin, and 10% FBS. Once
the cells migrated from the bone fragments to the plate and
reached the desired confluence, they were trypsinized
and replated in culture dishes to perform experiments.
Histomorphometric analysis
Mice were euthanized and the dissected bones fixed in
buffered 4% formalin (pH: 7.4) for 24 h, rinsed with PBS, and
stored in 70% ethanol until processing. Then were embedded
in methyl methacrylate plastic resin and cut into consecutive
longitudinal sections at 5 micron thickness for histomor-
phometric analysis. Osteoblast and osteoclast measurements
were performed on toluidine blue and acid phosphatase
tartrate-resistant (TRAP)/hematoxylin-stained sections, re-
spectively. Measurements were performed on two sections
separated by a distance of 40 lm, and then, data were pooled.
The region of interest was located at the distal metaphysis of
the femur starting 150 lm proximally from the growth plate
and extending 1.3 mm toward the diaphysis. The measure-
ment area excluded the 150 lm area adjacent to the cortical
bone. On the toluidine blue-stained slides, all cancellous
bone endosteal surface lengths were measured and catego-
rized as OS, or osteoblast surface (Ob.S), in the presence or
FIG. 7. Schematic representation of the proposed model for the bone-associated genes affected by the crosstalk
between tumor cells and PMOs, where the increase in the PTHrP levels in tumor cells due to the coculture could be
acting on the PMOs (Hmox1+/+ and +/-), stimulating Rankl expression. This mechanism would favor the osteoclast
differentiation and activation in the bone microenvironment. Hemin pretreatment of PCa cells interferes with the interaction
with bone cells, preventing the stimulation of PTHrP in the tumor cell and the change in Rankl levels in Hmox1+/+ PMOs,
leading toward a higher pro-osteoblastic profile. This modulatory effect is lost when compared with the coculture with the
Hmox1+/- PMOs, where despite hemin pretreatment, the induction of PTHrP in the tumor cell is maintained, and therefore,
Rankl increases in the Hmox1+/- PMOs. This mechanism appears as less sensitive in Hmox1-/- PMOs, since a greater
increase in PTHrP levels in the tumor cell is needed for an increase in Rankl levels in the Hmox1-/- PMOs. PTHrP,
parathyroid hormone-related protein. Color images are available online.
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absence of osteoid. For surfaces identified as osteoblast
surface, individual osteoblasts were counted and the data
pooled. All other surfaces were considered quiescent. For the
TRAP-stained slides, osteoclast surface (Oc.S) and/or ero-
sion surface (ES) were identified, surface lengths measured,
and the data pooled. For surface identified as Oc.S., the in-
dividual TRAP-positive, multinucleated osteoclasts were
counted and the data pooled. Surface that was rough and
scalloped in appearance, either with or without the pres-
ence of osteoclasts, was categorized as ES. The samples
were analyzed using a microscope Leica DM 1000 with a
20 · objective, coupled to a Qimaging Bioquant PV1
Camera for the acquisition of the images (at room tem-
perature; medium: air). The software Bioquant Osteo 2017
was used for imaging and analysis. Images were first cap-
tured in Bioquant Image Format (.bif) and then converted
to .tif format.
Cell lines
Human PC3 cells (ATCC CRL-1435) were obtained
from the American Type Culture Collection (Manassas, VA)
and routinely cultured in RPMI 1640 (Invitrogen, Carlsbad,
CA) supplemented with 10% FBS.
Hemin pretreatment of PCa cells and coculture system
An in vitro biocompartment culture system was used to
study the interaction between PCa cells and bone as pre-
viously described and slightly modified (67). Briefly, on
day 0, PC3 cells were seeded (100,000 cell/insert) in six-
well plate cell culture inserts (0.4-mm pore; Falcon/Becton
Dickinson Labware, Franklin Lakes, NJ), and on day 1,
they were treated with hemin (50 lM; Sigma-Aldrich, St
Louis, MO), a potent specific inducer of HO-1 (Hemin
PC3). Controls received fresh medium. The PMOs were
also seeded on day 1 in six-well tissue culture plates
(200,000 cells/well). On day 2, the inserts containing the
PC3 cells (pretreated or not with hemin) were extensively
washed with PBS. Then, the inserts were placed into tissue
culture plates containing the PMOs so that the two different
cell types shared the culture medium but were not in
physical contact. Coculturing of PC3 cells with PMOs was
performed with a-MEM plus 2% FBS for 24 h. On day 3,
the cells were collected and different parameters were an-
alyzed. As control, each cell type (PC3 cells pretreated
or not with hemin and PMOs) was grown alone. Cultures
were done in triplicate and each experiment was assayed
three times.
RNA isolation, complementary DNA synthesis,
and quantitative real-time polymerase chain reaction
Total RNA was extracted from cells using the TRIzol
(Life Technologies, Inc.) reagent followed by RNA extrac-
tion with chloroform, precipitation with isopropanol, and
washing with ethanol. RNA was then diluted in RNA-free
water, quantification was performed by ultraviolet absorbance
at 260 nm, and quality checked by measuring absorbance at
260/280 nm (Synergy HT; BioTek Instruments). RNA was
storaged at -80C until use. The RNA was reversed tran-
scribed as follows: 2 lg of total RNA was incubated with
oligo dTs and RNA-free water 10 min at 75C and rested
2 min on ice. Incubation for 30 min at 37C with dNTPs
(2.5 mM), DNase I (2 U/lL), and Rnase inhibitor (40 U/lL)
in a reaction buffer followed. Afterward, DNAse inactiva-
tion for 5 min at 75C took place. After resting on ice for
2 min, reverse transcriptase (200 U/lL) was added together
with Rnase inhibitor (40 U/lL) and complementary DNA
(cDNA)-synthesis occurred at 42C for 60 min. Samples
were stored at -20C subsequent to inactivation of reverse
transcriptase for 5 min at 94C. Real-time polymerase chain
reaction (PCR) amplifications were performed with SYBR
Green (Applied Biosystems) and an iQ5 Multicolor Real-
Time PCR Detection System (BioRad). Each amplification
reaction consisted of 1 lL cDNA, 6.5 lL SYBR Green PCR
mastermix, 2 lL RNAse free water, 3 lL primer mix, and
0.5 lL fluorescein (50 nM). Primers used are listed in Ta-
ble 1. PPIA and 36b4 were used as internal reference genes.
Data obtained were analyzed using the method of 2-DDCT
(38).
Assessment of ROS by flow cytometry
After the coculture, the PMOs were washed twice with
PBS and incubated with 6 lM 5,6-clorometil-2¢7¢-dichloro
Table 1. Table of Used Primers Containing the Gene Name, Species, Sequences, and Annealing Temperature
Gene Species Primer Fw (5¢ > 3¢) Primer Rv (5¢ > 3¢)
Annealing
temperature (C)
36b4 Mouse AAGCGCGTCCTGGCATTGTCT CCGCAGGGGCAGCAGTGGT 60
Hmox1 Mouse AAGAGGCTAAGACCGCCTTC GCATAAATTCCCACTGCCAC 60
Runx2 Mouse CCGCACGACAACCGCACCAT AGGCATTTCGGAGCTCGGCG 60
Rankl Mouse ATGGAAGGCTCATGGTTGGATG AAGAGGACAGAGTGACTTTATGGG 60
Casf1 Mouse CAACAGCTTTGCTAAGTGCTCTA CACTGCTAGGGGTGGCTTTA 60
Il-6 Mouse CTGCAAGAGACTTCCATCCAGTT GAAGTAGGGAAGGCCGTCG 60
Opg Mouse TGCTAATTCAGAAAGGAAATGC TGGTATAATCTTGGTAGGAACAG 58
Opn Mouse TCTCTTGGCTGAATTCTGAGG CTATAGGATCTGGGTGCAGGC 60
Col1a1 Mouse CATGTTCAGCTTTGTGGACCT GCAGCTGACTTCAGGGATGT 60
PPIA Human GGTATAAAAGGGGCGGGAGG CTGCAAACAGCTCAAAGGAGAC 60
HMOX1 Human ACTGCGTTCCTGCTCAACAT GGGGCAGAATCTTGCACTTT 60
PTHrP Human GTCTCAGCCGCCGCCTCAA GGAAGAATCGTCGCCGTAAA 60
OPG Human GAAGGGCGCTACCTTGAGAT GCA AACTGTATTTCGCTCTGG 59
Hmox1, heme oxygenase-1 gene.
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dihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA;
Invitrogen, Munich, Germany) for 1 h at 37C. Cells were
washed and incubated for 15 min in full medium. Cells were
then trypsinized and resuspended with PBS. H2DCFDA
levels were measured by flow cytometry in the fluorescein
isothiocyanate (FITC) channel (Attune NxT Flow Cyt-
ometer; Invitrogen, Munich, Germany) and analyzed with the
FlowJo 7.6 software.
Statistical analysis
All results are shown as mean – standard deviation
of three separate independent experiments unless stated
otherwise. RT-qPCR data sets were taken as paired samples
and analyzed using the repeated measures analysis of var-
iance (ANOVA) model. For other assays, the one-way
ANOVA was used. Tukey post-test was used to ascer-
tain statistical significance among the experimental con-
ditions with a threshold of p < 0.05 (*), p < 0.01 (**), and
p < 0.001 (***).
For gene expression level correlation analysis, the data
were processed for outlier detection using the confidence
ellipse method (1).
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Abbreviations Used
ANOVA¼ analysis of variance
BMPs¼ bone morphogenetic proteins
cDNA¼ complementary DNA
DKK1¼ inhibitor of Wnt/b-catenin pathway in bone
remodeling
ES¼ erosion surface
FBS¼ fetal bovine serum
H2DCFDA¼ 2¢7¢-dichloro dihydro-fluorescein diacetate
Het¼ heterozygous










PCR¼ polymerase chain reaction
PMOs¼ primary mouse osteoblasts
PTH¼ parathyroid hormone
PTHrP¼ parathyroid hormone-related protein
RANKL¼ receptor activator for nuclear factor j B ligand
ROS¼ reactive oxygen species
TRAP¼ acid phosphatase tartrate resistant
WT¼wild type
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